Status:
COMPLETED
Dexmedetomidine Versus Fentanyl on Postoperative Analgesic Profile in Laparoscopic Sleeve Gastrectomy
Lead Sponsor:
Helwan University
Conditions:
Pain, Postoperative
Eligibility:
All Genders
20-50 years
Phase:
NA
Brief Summary
Dexmedetomidine (Dex) activates the α2 adrenergic receptor that is present within the locus coeruleus, leading to anxiolysis, hypnosis, analgesia, and sedation. We conducted our research to compare t...
Detailed Description
The participants were assigned to two groups of equal size (32 patients in each group) by the use of computer-generated numbers and sealed opaque envelopes. The participants allocated to the DEX group...
Eligibility Criteria
Inclusion
- body mass index (BMI) of 35 kg/m2 or more.
- American Society of Anesthesiology (ASA) physical status of II-III.
- all participants would have a laparoscopic sleeve gastrectomy (LSG).
Exclusion
- allergy to α2 -adrenergic agonist.
- kidney, liver, neuromuscular disorders, and cardiac disease.
- or patients on opioid medications.
Key Trial Info
Start Date :
July 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2023
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06186895
Start Date
July 20 2021
End Date
May 20 2023
Last Update
January 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ryad Ghoraba
Tanta, Gharbia Governorate, Egypt, 31527